Abstract
(median age; 72 years; range; 45-91 years). The primary, assisted primary, and secondary patency rates at 1 year were 57%, 80%, and 89%, respectively. The amputationfree survival at 1 year was 92%. At 1 year, 82 % of the patients were free of endovascular reintervention. There were no early 30-day mortalities; however, six patients died within 1 year (4.8%). Eight patients underwent RFE in combination with a distal bypass, and all but one required multiple endovascular reinterventions within 1 year. All combined RFE/distal bypasses were patent at 1 year. Conclusions: Hyb revascularization allows for treatment of multilevel disease in CLI patients. Amputationfree survival at 1 year was 92%, and primary, assisted primary, and secondary patency rates were 57%, 80%, and 89%. Similarly, favorable results were seen with distal bypass surgery combined with RFE, with 100% patency rates at 1 year. Duplex surveillance and salvage angioplasty are essential in maintaining graft patency.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
